Skip to main content
AAN.com

Abstract

Background: Behavioral and cognitive problems are frequently encountered in juvenile myoclonic epilepsy (JME). The underlying mechanisms are unknown. Based on previous data showing that the dopamine system is involved in motor as well as cognitive functions, we tested whether JME may be associated with changes in this system, and if such changes are linked to interictal dysfunctions in these patients.
Method: PET and [11C]PE2I was used to investigate the regional binding potential to the dopamine transporter (DAT) in 12 patients with JME and 12 healthy controls. Binding potential was calculated in the midbrain, substantia nigra, caudate, and putamen. We also tested possible correlations between the respective measures and performance in several neuropsychological tests.
Results: Patients had a reduced binding potential in the substantia nigra and midbrain (p = 0.009 and 0.007), and normal values in the caudate and putamen. They also exhibited impaired psychomotor speed and motor function, which in some tests correlated with DAT binding potential in the midbrain.
Conclusion: Dopamine signaling seems impaired in the target regions for dopaminergic neurons (the striatum and frontal lobe), and related to several interictal dysfunctions in JME. The findings add a new aspect to the pathophysiology of JME.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (appendix_e-1.doc)
File (appendix_e-2.doc)
File (appendix_e-3.doc)
File (figure_e-1.pdf)
File (revised-from-au-at-proofs-appendix_table_e-1.doc)
File (table_e-2_and_e-3.doc)

REFERENCES

1.
Janz D. Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta Neurol Scand 1985;72:449–459.
2.
Swartz BE, Simpkins F, Halgren E, et al. Visual working memory in primary generalized epilepsy: an 18FDG-PET study. Neurology 1996;47:1203–1212.
3.
Devinsky O, Gershengorn J, Brown E, Perrine K, Vazquez B, Luciano D. Frontal functions in juvenile myoclonic epilepsy. Neuropsychiatry Neuropsychol Behav Neurol 1997;10:243–246.
4.
Bailet LL, Turk WR. The impact of childhood epilepsy on neurocognitive and behavioral performance: a prospective longitudinal study. Epilepsia 2000;41:426–431.
5.
Pascalicchio TF, de Araujo Filho GM, da Silva Noffs MH, et al. Neuropsychological profile of patients with juvenile myoclonic epilepsy: a controlled study of 50 patients. Epilepsy Behav 2007;10:263–267.
6.
Woermann FG, Free SL, Koepp MJ, Sisodiya SM, Duncan JS. Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI. Brain 1999;122 (Pt 11):2101–2108.
7.
Meschaks A, Lindstrom P, Halldin C, Farde L, Savic I. Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy. Arch Neurol 2005;62:946–950.
8.
Savic I, Lekvall A, Greitz D, Helms G. MR spectroscopy shows reduced frontal lobe concentrations of N-acetyl aspartate in patients with juvenile myoclonic epilepsy. Epilepsia 2000;41:290–296.
9.
Bernasconi A, Bernasconi N, Natsume J, Antel SB, Andermann F, Arnold DL. Magnetic resonance spectroscopy and imaging of the thalamus in idiopathic generalized epilepsy. Brain 2003;126 (Pt 11):2447–454.
10.
Mory SB, Li LM, Guerreiro CA, Cendes F. Thalamic dysfunction in juvenile myoclonic epilepsy: a proton MRS study. Epilepsia 2003;44:1402–1405.
11.
Helms G, Ciumas C, Kyaga S, Savic I. Increased thalamus levels of glutamate and glutamine (Glx) in patients with idiopathic generalised epilepsy. J Neurol Neurosurg Psychiatry 2006;77:489–494.
12.
Savic I, Osterman Y, Helms G. MRS shows syndrome differentiated metabolite changes in human-generalized epilepsies. Neuroimage 2004;21:163–172.
13.
Tae WS, Joo EY, Han SJ, Lee KH, Hong SB. CBF changes in drug naive juvenile myoclonic epilepsy patients. J Neurol 2007;254:1073–1080.
14.
Janz D. The idiopathic generalized epilepsies of adolescence with childhood and juvenile age of onset. Epilepsia 1997;38:4–11.
15.
Halldin C, Erixon-Lindroth N, Pauli S, et al. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 2003;30:1220–1230.
16.
Deransart C, Depaulis A. The control of seizures by the basal ganglia? A review of experimental data. Epileptic Disord 2002;4 Suppl 3:S61–72.
17.
Biraben A, Semah F, Ribeiro MJ, Douaud G, Remy P, Depaulis A. PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy. Neurology 2004;63:73–77.
18.
Bouilleret V, Semah F, Biraben A, et al. Involvement of the basal ganglia in refractory epilepsy: an 18F-Fluoro-L-DOPA PET study using 2 methods of analysis. J Nucl Med 2005;46:540–547.
19.
Greer CA, Alpern HP. Mediation of myoclonic seizures by dopamine and clonic seizures by acetylcholine and GABA. Life Sci 1977;21:385–392.
20.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
21.
Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005;57:229–238.
22.
Roland P, Graufeld CJ, Wahlin J, et al. Human brain atlas for high resolution functional and anatomical mapping. Hum Brain Mapp 1994;1:173–184.
23.
Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4 (3 Pt 1):153–158.
24.
Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol 2000;12:191–200.
25.
Ciumas C, Savic I. Structural changes in patients with primary generalized tonic and clonic seizures. Neurology 2006;67:683–686.
26.
Volkow ND, Ding YS, Fowler JS, et al. Dopamine transporters decrease with age. J Nucl Med 1996;37:554–559.
27.
Björklund A, Lindvall O. Dopamine-containing systems in the CNS. In: AB, TH, eds. Classical Transmitters in the CNS. Amsterdam: Elsevier, 1984: 55–122.
28.
Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000;27:867–869.
29.
Leroy C, Comtat C, Trebossen R, Syrota A, Martinot JL, Ribeiro MJ. Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med 2007;48:538–546.
30.
Canales JJ, Graybiel AM. A measure of striatal function predicts motor stereotypy. Nat Neurosci 2000;3:377–383.
31.
Erixon-Lindroth N, Farde L, Wahlin TB, Sovago J, Halldin C, Backman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res 2005;138:1–12.
32.
Ouchi Y, Yoshikawa E, Futatsubashi M, Okada H, Torizuka T, Sakamoto M. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study. J Cereb Blood Flow Metab 2002;22:746–752.
33.
Mortensen OV, Amara SG. Dynamic regulation of the dopamine transporter. Eur J Pharmacol 2003;479:159–170.
34.
Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53–83.
35.
Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996;47:626–635.
36.
Wang J, Michelhaugh SK, Bannon MJ. Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells. Eur J Neurosci 2007;25:1982–1986.
37.
Dodrill CB. A neuropsychological battery for epilepsy. Epilepsia 1978;19:611–623.
38.
Smith DB, Craft BR, Collins J, Mattson RH, Cramer JA. Behavioral characteristics of epilepsy patients compared with normal controls. Epilepsia 1986;27:760–768.
39.
Vesper J, Steinhoff B, Rona S, et al. Chronic high-frequency deep brain stimulation of the STN/SNr for progressive myoclonic epilepsy. Epilepsia 2007;48:1984–1989.

Information & Authors

Information

Published In

Neurology®
Volume 71Number 11September 9, 2008
Pages: 788-794
PubMed: 18463366

Publication History

Published online: May 7, 2008
Published in print: September 9, 2008

Permissions

Request permissions for this article.

Notes

Authors

Affiliations & Disclosures

C. Ciumas, MD, PhD
From the Department of Clinical Neuroscience, Division of Neurology (C.C., P.L., I.S.), Department of Neurobiology, Care Sciences and Society (T.-B.R.W.), Karolinska University Hospital, Woman and Child Health (A.J.), and Department of Clinical Neuroscience, Section of Psychiatry (C.H.), Karolinska Institutet, Stockholm; Stockholm Brain Institute (C.C., A.J., P.L., C.H., I.S.), Sweden; and Alzheimer’s Disease Research Unit (T.-B.R.W.), Discipline of Psychiatry, School of Medicine, The University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia.
T-B Robins Wahlin, PhD
From the Department of Clinical Neuroscience, Division of Neurology (C.C., P.L., I.S.), Department of Neurobiology, Care Sciences and Society (T.-B.R.W.), Karolinska University Hospital, Woman and Child Health (A.J.), and Department of Clinical Neuroscience, Section of Psychiatry (C.H.), Karolinska Institutet, Stockholm; Stockholm Brain Institute (C.C., A.J., P.L., C.H., I.S.), Sweden; and Alzheimer’s Disease Research Unit (T.-B.R.W.), Discipline of Psychiatry, School of Medicine, The University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia.
A. Jucaite, MD, PhD
From the Department of Clinical Neuroscience, Division of Neurology (C.C., P.L., I.S.), Department of Neurobiology, Care Sciences and Society (T.-B.R.W.), Karolinska University Hospital, Woman and Child Health (A.J.), and Department of Clinical Neuroscience, Section of Psychiatry (C.H.), Karolinska Institutet, Stockholm; Stockholm Brain Institute (C.C., A.J., P.L., C.H., I.S.), Sweden; and Alzheimer’s Disease Research Unit (T.-B.R.W.), Discipline of Psychiatry, School of Medicine, The University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia.
P. Lindstrom, MD, PhD
From the Department of Clinical Neuroscience, Division of Neurology (C.C., P.L., I.S.), Department of Neurobiology, Care Sciences and Society (T.-B.R.W.), Karolinska University Hospital, Woman and Child Health (A.J.), and Department of Clinical Neuroscience, Section of Psychiatry (C.H.), Karolinska Institutet, Stockholm; Stockholm Brain Institute (C.C., A.J., P.L., C.H., I.S.), Sweden; and Alzheimer’s Disease Research Unit (T.-B.R.W.), Discipline of Psychiatry, School of Medicine, The University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia.
C. Halldin, PhD
From the Department of Clinical Neuroscience, Division of Neurology (C.C., P.L., I.S.), Department of Neurobiology, Care Sciences and Society (T.-B.R.W.), Karolinska University Hospital, Woman and Child Health (A.J.), and Department of Clinical Neuroscience, Section of Psychiatry (C.H.), Karolinska Institutet, Stockholm; Stockholm Brain Institute (C.C., A.J., P.L., C.H., I.S.), Sweden; and Alzheimer’s Disease Research Unit (T.-B.R.W.), Discipline of Psychiatry, School of Medicine, The University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia.
I. Savic, MD, PhD
From the Department of Clinical Neuroscience, Division of Neurology (C.C., P.L., I.S.), Department of Neurobiology, Care Sciences and Society (T.-B.R.W.), Karolinska University Hospital, Woman and Child Health (A.J.), and Department of Clinical Neuroscience, Section of Psychiatry (C.H.), Karolinska Institutet, Stockholm; Stockholm Brain Institute (C.C., A.J., P.L., C.H., I.S.), Sweden; and Alzheimer’s Disease Research Unit (T.-B.R.W.), Discipline of Psychiatry, School of Medicine, The University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia.

Notes

Address correspondence and reprint requests to Dr. Ivanka Savic, Stockholm Brain Institute, Karolinska Institutet, Dept. of Clinical Neuroscience, Karolinska University Hospital, MR Centre, 171 76 Stockholm, Sweden [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Dopamine depletion in wistar rats with epilepsy, Brazilian Journal of Biology, 84, (2024).https://doi.org/10.1590/1519-6984.248411
    Crossref
  2. Acute effects of Mozart K.448 on interictal epileptiform discharges in adult patients with drug-resistant focal epilepsy: A crossover randomized controlled trial, Seizure: European Journal of Epilepsy, 123, (66-73), (2024).https://doi.org/10.1016/j.seizure.2024.10.016
    Crossref
  3. FAME4-associating YEATS2 knockdown impairs dopaminergic synaptic integrity and leads to seizure-like behaviours in Drosophila melanogaster, Progress in Neurobiology, 233, (102558), (2024).https://doi.org/10.1016/j.pneurobio.2023.102558
    Crossref
  4. Comparative analysis of processing speed impairments in TLE, FLE, and GGE: Theoretical insights and clinical Implications, Epilepsy & Behavior Reports, 28, (100722), (2024).https://doi.org/10.1016/j.ebr.2024.100722
    Crossref
  5. Transcranial brain parenchyma sonography in patients with juvenile myoclonic epilepsy, Acta Neurologica Belgica, 124, 4, (1335-1342), (2024).https://doi.org/10.1007/s13760-024-02561-6
    Crossref
  6. Antidepressant and Anxiolytic Effects of L-Methionine in the WAG/Rij Rat Model of Depression Comorbid with Absence Epilepsy, International Journal of Molecular Sciences, 24, 15, (12425), (2023).https://doi.org/10.3390/ijms241512425
    Crossref
  7. SLCO5A1 and synaptic assembly genes contribute to impulsivity in juvenile myoclonic epilepsy, npj Genomic Medicine, 8, 1, (2023).https://doi.org/10.1038/s41525-023-00370-z
    Crossref
  8. Midbrain structure volume, estimated myelin and functional connectivity in idiopathic generalised epilepsy, Epilepsy & Behavior, 140, (109084), (2023).https://doi.org/10.1016/j.yebeh.2023.109084
    Crossref
  9. Development and Validation of MRI-Based Radiomics Models for Diagnosing Juvenile Myoclonic Epilepsy, Korean Journal of Radiology, 23, 12, (1281), (2022).https://doi.org/10.3348/kjr.2022.0539
    Crossref
  10. Mozart effect in patients with epilepsy, Epilepsy and paroxysmal conditions, 13, 3, (264-273), (2021).https://doi.org/10.17749/2077-8333/epi.par.con.2021.061
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share